Medicine & Pharmaceuticals

Latest News Releases

*DISCLAIMER*: Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

Medicine & Pharmaceuticals News Releases via PRNewswireMore>>
Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder
Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder
Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of...More>>
Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of...More>>
Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that...More>>
Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that...More>>
Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose groups. The primary...More>>
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose groups. The primary...More>>
Transition to Propellant-Free Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray Nears Completion
Transition to Propellant-Free Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray Nears Completion
As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals (HCPs) and...More>>
As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals (HCPs) and...More>>
Collegium Pharmaceutical's CEO to Present at the UBS Global Health Care Conference in New York on May 20, 2013
Collegium Pharmaceutical's CEO to Present at the UBS Global Health Care Conference in New York on May 20, 2013
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Monday, May 20, 2013 at...More>>
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Monday, May 20, 2013 at...More>>
Eisai Highlights New Research On Melanoma, Breast and Endometrial Cancer at ASCO Annual Meeting
Eisai Highlights New Research On Melanoma, Breast and Endometrial Cancer at ASCO Annual Meeting
Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO),...More>>
Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO),...More>>
Nevada Donor Network Announces Unprecedented Growth In Organ & Tissue Donation
Nevada Donor Network Announces Unprecedented Growth In Organ & Tissue Donation
Nevada Donor Network is proud to announce record breaking increases in all aspects of organ and tissue donation. Our staff facilitated donations from 75 organ donors, 296 tissue donors and 546 cornea donors during 2012. The...More>>
Nevada Donor Network is proud to announce record breaking increases in all aspects of organ and tissue donation. Our staff facilitated donations from 75 organ donors, 296 tissue donors and 546 cornea donors during 2012. The...More>>
ThromboGenics Business Update
ThromboGenics Business Update
JETREA® gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million Phase IIa study evaluating JETREA® in wet AMD patients shows 24% VMA resolution rate for JETREA® treated...More>>
JETREA® gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million Phase IIa study evaluating JETREA® in wet AMD patients shows 24% VMA resolution rate for JETREA® treated...More>>
New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy
New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy
A new survey of more than 3,000 postmenopausal women reveals that women living with vulvar and vaginal atrophy (VVA) are either unaware of what causes this progressive and chronic condition, or are simply dissatisfied with...More>>
A new survey of more than 3,000 postmenopausal women reveals that women living with vulvar and vaginal atrophy (VVA) are either unaware of what causes this progressive and chronic condition, or are simply dissatisfied with...More>>
Growing Opportunities in the Construction, Pharma and E-learning Sectors in India
Growing Opportunities in the Construction, Pharma and E-learning Sectors in India
The construction sector in India The construction industry in India is the second largest in the country, after agriculture. It has been an integral part of the Indian economy and has been consistently contributing around...More>>
The construction sector in India The construction industry in India is the second largest in the country, after agriculture. It has been an integral part of the Indian economy and has been consistently contributing around...More>>
Breakthrough Method for Lipid Analysis in Fecal Material Developed; New Understanding of Diseases/Disorders Related to Gut Function Possible
Breakthrough Method for Lipid Analysis in Fecal Material Developed; New Understanding of Diseases/Disorders Related to Gut Function Possible
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced the publication in the journal Analytical Chemistry of a study by a team of scientists led by Dr. Bruce Kristal, Associate Professor of...More>>
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced the publication in the journal Analytical Chemistry of a study by a team of scientists led by Dr. Bruce Kristal, Associate Professor of...More>>
Syneron Introduces Enhancements to its Innovative Body Shaping Products
Syneron Introduces Enhancements to its Innovative Body Shaping Products
Expands treatment capabilities, reduces treatment time, and improves overall experience with UltraShape and VelaShape systems Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, announced today...More>>
Expands treatment capabilities, reduces treatment time, and improves overall experience with UltraShape and VelaShape systems Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, announced today...More>>
Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company...More>>
Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company...More>>
Football Legend Jerome Bettis & Sanofi US Tackle Anaphylaxis During National Asthma and Allergy Awareness Month
Football Legend Jerome Bettis & Sanofi US Tackle Anaphylaxis During National Asthma and Allergy Awareness Month
Professional football icon Jerome Bettis and Sanofi US, the makers of Auvi-Q™ (epinephrine injection, USP), have teamed up to raise awareness about severe allergic reactions (anaphylaxis) and introduce The Severe Allergy...More>>
Professional football icon Jerome Bettis and Sanofi US, the makers of Auvi-Q™ (epinephrine injection, USP), have teamed up to raise awareness about severe allergic reactions (anaphylaxis) and introduce The Severe Allergy...More>>
DiagnoCure announces presentation on Previstage GCC at the 2013 ASCO annual meeting
DiagnoCure announces presentation on Previstage GCC at the 2013 ASCO annual meeting
New findings validate clinical utility in Colorectal Cancer StagingMore>>
New findings validate clinical utility in Colorectal Cancer StagingMore>>
Echo Therapeutics to Unveil Symphony® CGM System in Webcast
Echo Therapeutics to Unveil Symphony® CGM System in Webcast
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the unveiling and demonstration...More>>
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the unveiling and demonstration...More>>
Shengtai Pharmaceutical, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results
Shengtai Pharmaceutical, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "We" or "Us" or "Our"), a manufacturer and distributor in China of glucose and starch as...More>>
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "We" or "Us" or "Our"), a manufacturer and distributor in China of glucose and starch as...More>>
AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual...More>>
AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual...More>>
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug...More>>
Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug...More>>
Mathew Whelan Joins Remedi SeniorCare® as Vice President and Corporate Controller
Mathew Whelan Joins Remedi SeniorCare® as Vice President and Corporate Controller
Remedi SeniorCare® has named Mathew Whelan as Vice President and Corporate Controller. With over 20 years of experience building and leading accounting teams, Matt will serve as a key member of the corporate financial team...More>>
Remedi SeniorCare® has named Mathew Whelan as Vice President and Corporate Controller. With over 20 years of experience building and leading accounting teams, Matt will serve as a key member of the corporate financial team...More>>
Life After Failing TVM Treatments is a Rollercoaster of Side Effects for Women
Life After Failing TVM Treatments is a Rollercoaster of Side Effects for Women
Imagine what it would feel like to have a cheese grater wearing at your tissue every time you moved. For women with transvaginal mesh (TVM) implants this stomach wrenching analogy can hit home all too closely. Complications...More>>
Imagine what it would feel like to have a cheese grater wearing at your tissue every time you moved. For women with transvaginal mesh (TVM) implants this stomach wrenching analogy can hit home all too closely. Complications...More>>
Veloxis Pharmaceuticals announces financial results for the first three months of 2013
Veloxis Pharmaceuticals announces financial results for the first three months of 2013
Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-T
Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-T
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS. The data, which demonstrate that SB-728-T treatment results in a...More>>
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS. The data, which demonstrate that SB-728-T treatment results in a...More>>
International Isotopes Inc. Announces First Quarter 2013 Financial Results
International Isotopes Inc. Announces First Quarter 2013 Financial Results
International Isotopes Inc. (OTC Bulletin Board: INIS) announces financial results for the first quarter ended March 31, 2013.More>>
International Isotopes Inc. (OTC Bulletin Board: INIS) announces financial results for the first quarter ended March 31, 2013.More>>
New Web Radio Show "Alzheimer's Answers" Gives Callers Live Access to Alzheimer's Disease Expert Dr. William Van Horn
New Web Radio Show "Alzheimer's Answers" Gives Callers Live Access to Alzheimer's Disease Expert Dr. William Van Horn
Dr. William Van Horn, a recognized expert in the prevention and treatment of Alzheimer's disease, is now hosting a web radio show to share his unique experiences with listeners and answer callers' questions. The...More>>
Dr. William Van Horn, a recognized expert in the prevention and treatment of Alzheimer's disease, is now hosting a web radio show to share his unique experiences with listeners and answer callers' questions. The...More>>
Peregrine Health Services Selects COMS Interactive
Peregrine Health Services Selects COMS Interactive
Peregrine Health Services, Inc. (Peregrine), is a well-respected Midwest long-term care organization, that is deploying Daylight IQ™, the COMS Interactive (Clinical Outcomes Management System or COMS) product suite, as a key...More>>
Peregrine Health Services, Inc. (Peregrine), is a well-respected Midwest long-term care organization, that is deploying Daylight IQ™, the COMS Interactive (Clinical Outcomes Management System or COMS) product suite, as a key...More>>
Mast Therapeutics Reports First Quarter 2013 Financial Results
Mast Therapeutics Reports First Quarter 2013 Financial Results
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2013.More>>
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2013.More>>
New Published Clinical Study Shows Masimo PVI® Helps Clinicians Assess Fluid Responsiveness in Pediatric Patients
New Published Clinical Study Shows Masimo PVI® Helps Clinicians Assess Fluid Responsiveness in Pediatric Patients
Masimo (NASDAQ: MASI) announced today a new study in the British Journal of Anesthesia demonstrates that Masimo's noninvasive PVI® can be used to help clinicians accurately assess fluid responsiveness in mechanically...More>>
Masimo (NASDAQ: MASI) announced today a new study in the British Journal of Anesthesia demonstrates that Masimo's noninvasive PVI® can be used to help clinicians accurately assess fluid responsiveness in mechanically...More>>
VirtualScopics Reports First Quarter 2013 Results
VirtualScopics Reports First Quarter 2013 Results
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging, today announced revenues of $2,532,587 for the quarter ended March 31, 2013 compared to $3,702,159 for the quarter ended March 31, 2012. Net...More>>
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging, today announced revenues of $2,532,587 for the quarter ended March 31, 2013 compared to $3,702,159 for the quarter ended March 31, 2012. Net...More>>
Personalized Medicine Market Analysis
Personalized Medicine Market Analysis
Reportlinker.com announces that a new market research report is available in its catalogue:More>>
Reportlinker.com announces that a new market research report is available in its catalogue:More>>
Nuvo Research granted U.S. Patent for treatment of allergic rhinitis and allergic asthma with WF10
Nuvo Research granted U.S. Patent for treatment of allergic rhinitis and allergic asthma with WF10
MISSISSAUGA, ON, May 14, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune...More>>
MISSISSAUGA, ON, May 14, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune...More>>
GenoVive, a pioneer in DNA-based weight management solutions, today announced the company's first European partnership as of May 1, 2013 with DNADIETA based in Poland.
GenoVive, a pioneer in DNA-based weight management solutions, today announced the company's first European partnership as of May 1, 2013 with DNADIETA based in Poland.
GenoVive is forming worldwide partnerships and is engaged in discussions with several countries in Europe and other continents to bring its "Weight Loss Designed by Science" program internationally. Vic Castellon, PhamD....More>>
GenoVive is forming worldwide partnerships and is engaged in discussions with several countries in Europe and other continents to bring its "Weight Loss Designed by Science" program internationally. Vic Castellon, PhamD....More>>
Craft Brewers Nationwide Join the ALS Therapy Development Institute in the 'Ales for ALS' Campaign to Battle Lou Gehrig's Disease
Craft Brewers Nationwide Join the ALS Therapy Development Institute in the 'Ales for ALS' Campaign to Battle Lou Gehrig's Disease
The ALS Therapy Development Institute (ALS TDI) announced today that 38 microbrewers across the country have joined the Ales for ALS campaign in support of ALS TDI's mission to discover and develop effective treatments...More>>
The ALS Therapy Development Institute (ALS TDI) announced today that 38 microbrewers across the country have joined the Ales for ALS campaign in support of ALS TDI's mission to discover and develop effective treatments...More>>
Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers that have become resistant to standard treatments, announced today the publication in...More>>
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers that have become resistant to standard treatments, announced today the publication in...More>>
Nutrastar Announces First Quarter 2013 Results, Maintains Full Year Revenue Guidance Range of $44 million to $46 Million
Nutrastar Announces First Quarter 2013 Results, Maintains Full Year Revenue Guidance Range of $44 million to $46 Million
Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" or the "Company"), a leading producer and supplier of premium branded consumer products, including commercially cultivated Cordyceps Militaris ("Cordyceps"), functional...More>>
Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" or the "Company"), a leading producer and supplier of premium branded consumer products, including commercially cultivated Cordyceps Militaris ("Cordyceps"), functional...More>>
TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets
TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets
TWi Pharmaceuticals, Inc. (Taiwan OTC: 4180) today announced that it has received tentative approval for its Abbreviated New Drug Application (ANDA) for Guanfacine Hydrochloride Extended Release Tablets 1mg, 2mg, 3mg and 4mg...More>>
TWi Pharmaceuticals, Inc. (Taiwan OTC: 4180) today announced that it has received tentative approval for its Abbreviated New Drug Application (ANDA) for Guanfacine Hydrochloride Extended Release Tablets 1mg, 2mg, 3mg and 4mg...More>>
Gluten-Free Products Market Worth $6,206.2 Million by 2018
Gluten-Free Products Market Worth $6,206.2 Million by 2018
The report "Gluten-Free Products Market By Type (Bakery & Confectionery, Snacks, Breakfast Cereals, Baking Mixes & Flour, Meat & Poultry Products), Sales Channel (Natural & Conventional) &...More>>
The report "Gluten-Free Products Market By Type (Bakery & Confectionery, Snacks, Breakfast Cereals, Baking Mixes & Flour, Meat & Poultry Products), Sales Channel (Natural & Conventional) &...More>>
Domestic Production of Medical Isotope Mo-99 Moves a Step Closer at Los Alamos
Domestic Production of Medical Isotope Mo-99 Moves a Step Closer at Los Alamos
Today, Los Alamos National Laboratory announced that for the first time, irradiated uranium fuel has been recycled and reused for molybdenum-99 (Mo-99) production, with virtually no losses in Mo-99 yields or uranium...More>>
Today, Los Alamos National Laboratory announced that for the first time, irradiated uranium fuel has been recycled and reused for molybdenum-99 (Mo-99) production, with virtually no losses in Mo-99 yields or uranium...More>>
Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business
Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business
BELLEVILLE, ON, May 13, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has engaged U.S.-based Evercore...More>>
BELLEVILLE, ON, May 13, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has engaged U.S.-based Evercore...More>>
SPO Reports Results for First Quarter 2013
SPO Reports Results for First Quarter 2013
SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today financial results for the fiscal quarter ended March 31, 2013. Total revenue...More>>
SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today financial results for the fiscal quarter ended March 31, 2013. Total revenue...More>>
Assessing Your Asthma is Key to Taking Control
Assessing Your Asthma is Key to Taking Control
Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by...More>>
Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by...More>>
Thermic Fluid Market is Expected to Reach USD 2.78 Billion Globally by 2018: Transparency Market Research
Thermic Fluid Market is Expected to Reach USD 2.78 Billion Globally by 2018: Transparency Market Research
According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Thermic Fluid Market by Product (Silicone and Aromatics, Mineral Oils, GlycolBased Fluids, etc.), by...More>>
According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Thermic Fluid Market by Product (Silicone and Aromatics, Mineral Oils, GlycolBased Fluids, etc.), by...More>>
NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative
NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative
NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3...More>>
NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3...More>>
Cardiome Reports First Quarter Results
Cardiome Reports First Quarter Results
Cardiome to conduct conference call and webcast today, May 13, at 4:15 p.m. Eastern (1:15 p.m. Pacific)More>>
Cardiome to conduct conference call and webcast today, May 13, at 4:15 p.m. Eastern (1:15 p.m. Pacific)More>>
New Clinical Studies Presented at the International Anesthesia Research Society Annual Meeting Show Benefits of Masimo Noninvasive Patient Monitoring Technologies: SpHb®, RRa™, and SedLine®
New Clinical Studies Presented at the International Anesthesia Research Society Annual Meeting Show Benefits of Masimo Noninvasive Patient Monitoring Technologies: SpHb®, RRa™, and SedLine®
Masimo (NASDAQ: MASI) announced today that three new clinical studies evaluating Masimo noninvasive patient monitoring technologies were presented before the world's leading anesthesia educators and investigators at the...More>>
Masimo (NASDAQ: MASI) announced today that three new clinical studies evaluating Masimo noninvasive patient monitoring technologies were presented before the world's leading anesthesia educators and investigators at the...More>>
Endo Health Solutions Responds to FDA's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone
Endo Health Solutions Responds to FDA's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone
Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that the U.S. Food and Drug Administration (FDA) has denied a Citizen Petition filed by its subsidiary, Endo Pharmaceuticals Inc. Endo presented FDA data collected...More>>
Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that the U.S. Food and Drug Administration (FDA) has denied a Citizen Petition filed by its subsidiary, Endo Pharmaceuticals Inc. Endo presented FDA data collected...More>>
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of...More>>
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of...More>>
Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
Bernstein Liebhard LLP today announced that a securities class action has been commenced in the United States District Court for the District of Massachusetts on behalf of a class (the "Class") of purchasers of Aveo...More>>
Bernstein Liebhard LLP today announced that a securities class action has been commenced in the United States District Court for the District of Massachusetts on behalf of a class (the "Class") of purchasers of Aveo...More>>
Echo Therapeutics Announces First Quarter 2013 Financial Results
Echo Therapeutics Announces First Quarter 2013 Financial Results
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the...More>>
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the...More>>
Life Care Medical Devices Ltd Announces Addition Of Dublin, Ireland Based European Subsidiary
Life Care Medical Devices Ltd Announces Addition Of Dublin, Ireland Based European Subsidiary
Life Care Medical Devices Ltd (OTCBB:LCMD) today announced the opening of their European subsidiary offices in Dublin, Ireland. Life Care Medical Devices Ltd, Ireland will manage all aspects of the company's European...More>>
Life Care Medical Devices Ltd (OTCBB:LCMD) today announced the opening of their European subsidiary offices in Dublin, Ireland. Life Care Medical Devices Ltd, Ireland will manage all aspects of the company's European...More>>
Cardiome To Present At Bloom Burton & Co. Healthcare Investor Conference
Cardiome To Present At Bloom Burton & Co. Healthcare Investor Conference
NASDAQ: CRME TSX: COMMore>>
NASDAQ: CRME TSX: COMMore>>
Concord Medical to Report First Quarter 2013 Financial Results on May 21, 2013
Concord Medical to Report First Quarter 2013 Financial Results on May 21, 2013
Conference call to discuss results will be held on May 22, 2013More>>
Conference call to discuss results will be held on May 22, 2013More>>
Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
Clinically and Statistically Significant Reduction of Chronic Pruritus (Itch) Seen in Psoriasis Patients Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline...More>>
Clinically and Statistically Significant Reduction of Chronic Pruritus (Itch) Seen in Psoriasis Patients Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline...More>>
ScinoPharm Taiwan and Coland Holdings Establish Strategic Alliance for Oncological Injectable Products for China
ScinoPharm Taiwan and Coland Holdings Establish Strategic Alliance for Oncological Injectable Products for China
ScinoPharm Taiwan Ltd. (TSE: 1789.TW) and Coland Holdings Ltd. (TSE: 4144.TW) announced today that they have formed a strategic alliance to develop a series of generic oncological drugs for Mainland China. Several Active...More>>
ScinoPharm Taiwan Ltd. (TSE: 1789.TW) and Coland Holdings Ltd. (TSE: 4144.TW) announced today that they have formed a strategic alliance to develop a series of generic oncological drugs for Mainland China. Several Active...More>>
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Amgen (NASDAQ:AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the...More>>
Amgen (NASDAQ:AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the...More>>
From "Wall-less Hospitals" to Skin-Embedded Chips: Predictions for the Future of Health Tech
From "Wall-less Hospitals" to Skin-Embedded Chips: Predictions for the Future of Health Tech
As part of its upcoming Health:Refactored conference, Health 2.0 wants to help elopers and designers envision the future of health tech -- a future wide open for them to create. This inaugural, first-of-a-kind conference is...More>>
As part of its upcoming Health:Refactored conference, Health 2.0 wants to help developers and designers envision the future of health tech -- a future wide open for them to create. This inaugural, first-of-a-kind conference...More>>
Infinity Group Signs Agreement in Hall of the People in Ceremony Attended by the Prime Ministers of Israel and China
Infinity Group Signs Agreement in Hall of the People in Ceremony Attended by the Prime Ministers of Israel and China
Infinity Group, a cross-border platform, announced today that it signed a memorandum of understanding with China this week in the Hall of the People in Beijing in the presence of Prime Minister of China Li Keqaing and Prime...More>>
Infinity Group, a cross-border platform, announced today that it signed a memorandum of understanding with China this week in the Hall of the People in Beijing in the presence of Prime Minister of China Li Keqaing and Prime...More>>
Former FDA Official Tim Cote Joins Emmaus Medical as Regulatory Advisor
Former FDA Official Tim Cote Joins Emmaus Medical as Regulatory Advisor
Timothy Cote, M.D., MPH, former director of the Office of Orphan Product Development of the U.S. Food and Drug Administration, has joined Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, in...More>>
Timothy Cote, M.D., MPH, former director of the Office of Orphan Product Development of the U.S. Food and Drug Administration, has joined Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, in...More>>
Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2%
Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2%
MISSISSAUGA, ON, May 9, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European...More>>
MISSISSAUGA, ON, May 9, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European...More>>
BioScrip Reports First Quarter 2013 Financial Results
BioScrip Reports First Quarter 2013 Financial Results
BioScrip, Inc. (NASDAQ: BIOS) today announced 2013 first quarter financial results. First quarter revenue from continuing operations was $199.1 million and the net loss from continuing operations was $7.5 million, or $0.13...More>>
BioScrip, Inc. (NASDAQ: BIOS) today announced 2013 first quarter financial results. First quarter revenue from continuing operations was $199.1 million and the net loss from continuing operations was $7.5 million, or $0.13...More>>
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results
(all figures are in Canadian dollars unless otherwise noted)More>>
(all figures are in Canadian dollars unless otherwise noted)More>>
Hologic Appoints Scott Garrett to Board of Directors
Hologic Appoints Scott Garrett to Board of Directors
Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare...More>>
Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare...More>>
Transcept Pharmaceuticals Reports First Quarter 2013 Financial Results
Transcept Pharmaceuticals Reports First Quarter 2013 Financial Results
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of...More>>
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of...More>>
BINOSTO® (alendronate sodium) Featured on Two National Programs
BINOSTO® (alendronate sodium) Featured on Two National Programs
About half of all women over age 50 and 1 in 4 men will break a bone due to osteoporosis. Yet the disease, which causes bones to become fragile and more likely to fracture, remains poorly understood, according to...More>>
About half of all women over age 50 and 1 in 4 men will break a bone due to osteoporosis. Yet the disease, which causes bones to become fragile and more likely to fracture, remains poorly understood, according to...More>>
Exosome Diagnostics Presents Data Demonstrating Utility of Urine Exosome Technology to Predict Prostate Biopsy Outcome at American Urological Association Annual Meeting
Exosome Diagnostics Presents Data Demonstrating Utility of Urine Exosome Technology to Predict Prostate Biopsy Outcome at American Urological Association Annual Meeting
Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic products for use in personalized medicine research and clinical diagnostics, today announced the presentation of data at the American Urological...More>>
Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic products for use in personalized medicine research and clinical diagnostics, today announced the presentation of data at the American Urological...More>>
Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE® in the U.S.
Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE® in the U.S.
Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that they have entered into an exclusive U.S. license and supply agreement with Teva Pharmaceutical Industries Ltd (NYSE: TEVA) for ADASUVE® (Staccato® loxapine). ...More>>
Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that they have entered into an exclusive U.S. license and supply agreement with Teva Pharmaceutical Industries Ltd (NYSE: TEVA) for ADASUVE® (Staccato® loxapine). ...More>>
Teva and Alexza Announce Teva's License to Market ADASUVE® in the U.S.
Teva and Alexza Announce Teva's License to Market ADASUVE® in the U.S.
Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that the companies have entered into an exclusive U.S. license...More>>
Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that the companies have entered into an exclusive U.S. license...More>>
Healthcare Trust of America, Inc. Reports 23.1% Increase In Normalized FFO Per Share and 3.4% Same-Property Growth
Healthcare Trust of America, Inc. Reports 23.1% Increase In Normalized FFO Per Share and 3.4% Same-Property Growth
Healthcare Trust of America, Inc. (NYSE: HTA) ("HTA") announced results for the quarter ended March 31, 2013.More>>
Healthcare Trust of America, Inc. (NYSE: HTA) ("HTA") announced results for the quarter ended March 31, 2013.More>>
Takeda to Acquire Inviragen, Inc.
Takeda to Acquire Inviragen, Inc.
Takeda Pharmaceutical Company Limited ("Takeda") and Inviragen, Inc. ("Inviragen") jointly announced today that Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a...More>>
Takeda Pharmaceutical Company Limited ("Takeda") and Inviragen, Inc. ("Inviragen") jointly announced today that Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a...More>>
Bayer commences cash tender offer for all outstanding shares of Conceptus, Inc.
Bayer commences cash tender offer for all outstanding shares of Conceptus, Inc.
Bayer's planned acquisition of Conceptus, Inc., based in Mountain View, California (NASDAQ: CPTS) is entering its next phase: Evelyn Acquisition Company, a subsidiary established by Bayer HealthCare LLC, Tarrytown, N.Y.,...More>>
Bayer's planned acquisition of Conceptus, Inc., based in Mountain View, California (NASDAQ: CPTS) is entering its next phase: Evelyn Acquisition Company, a subsidiary established by Bayer HealthCare LLC, Tarrytown, N.Y.,...More>>
Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results
Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results
All amounts are in U.S. dollars (unless otherwise noted)More>>
All amounts are in U.S. dollars (unless otherwise noted)More>>
Accuray Announces Results for Third Quarter Fiscal 2013
Accuray Announces Results for Third Quarter Fiscal 2013
Accuray Incorporated (Nasdaq: ARAY) today announced financial results for the third quarter of fiscal 2013 that ended March 31, 2013. Non-GAAP results are provided to enhance understanding of Accuray's ongoing core...More>>
Accuray Incorporated (Nasdaq: ARAY) today announced financial results for the third quarter of fiscal 2013 that ended March 31, 2013. Non-GAAP results are provided to enhance understanding of Accuray's ongoing core...More>>
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter ended March 31, 2013, updated 2013 financial guidance and key additions to its board of directors.More>>
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter ended March 31, 2013, updated 2013 financial guidance and key additions to its board of directors.More>>
Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer
Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer
Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix® (panitumumab) versus Erbitux® (cetuximab) as a single agent for the treatment of chemorefractory metastatic...More>>
Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix® (panitumumab) versus Erbitux® (cetuximab) as a single agent for the treatment of chemorefractory metastatic...More>>
Transition Therapeutics Announces Third Quarter Fiscal 2013 Financial Results
Transition Therapeutics Announces Third Quarter Fiscal 2013 Financial Results
TORONTO, May 7, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with...More>>
TORONTO, May 7, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with...More>>
Piramal Imaging Welcomes Ana M. Catafau, M.D., Ph.D., as VP, Clinical Research and Development, Neurosciences
Piramal Imaging Welcomes Ana M. Catafau, M.D., Ph.D., as VP, Clinical Research and Development, Neurosciences
Piramal Imaging SA, a division of Piramal Enterprises, today announced Ana M. Catafau, M.D., Ph.D., has joined the company as vice president (VP) of Clinical Research and Development, Neurosciences.More>>
Piramal Imaging SA, a division of Piramal Enterprises, today announced Ana M. Catafau, M.D., Ph.D., has joined the company as vice president (VP) of Clinical Research and Development, Neurosciences.More>>
Psychemedics Corporation Announces Record First Quarter Revenues
Psychemedics Corporation Announces Record First Quarter Revenues
Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2013. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of...More>>
Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2013. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of...More>>
Pivotal Therapeutics VASCAZEN®-REVEAL trial meets primary and secondary endpoints - VASCAZEN® shows 121% correction of an Omega-3 deficiency (p< 0.0001) with a concomittant 48% reduction in triglycerides (p<0.0005)
Pivotal Therapeutics VASCAZEN®-REVEAL trial meets primary and secondary endpoints - VASCAZEN® shows 121% correction of an Omega-3 deficiency (p< 0.0001) with a concomittant 48% reduction in triglycerides (p<0.0005)
WOODBRIDGE, ON, May 7, 2013 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health,...More>>
WOODBRIDGE, ON, May 7, 2013 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health,...More>>
Leading Nonprofit Reveals Top Five Reasons Why More Moms Turn to Alcohol and Drugs
Leading Nonprofit Reveals Top Five Reasons Why More Moms Turn to Alcohol and Drugs
The pressures on mothers today are extraordinary. Experts share tips daily on how to "be a better mom" and "have it all." While this wealth of information can be valuable, it also sets an impossible standard for mothers to...More>>
The pressures on mothers today are extraordinary. Experts share tips daily on how to "be a better mom" and "have it all." While this wealth of information can be valuable, it also sets an impossible standard for mothers to...More>>
AMRI Announces First Quarter 2013 Results and Raises EPS Guidance for the Year
AMRI Announces First Quarter 2013 Results and Raises EPS Guidance for the Year
AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2013.More>>
AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2013.More>>
CPhI China 2013 Increases Customer Content Services and Expands Thanks to a Double Digit Pharma Industry Growth Rate and a Burgeoning Generics Market
CPhI China 2013 Increases Customer Content Services and Expands Thanks to a Double Digit Pharma Industry Growth Rate and a Burgeoning Generics Market
Co-located events P-MEC/ICSE/BioPh/InnoPack/LABWorld are helping to build improved partnerships and drive GMP standards across the region CPhI announces that CPhI China, an event organised by UBM Live and UBM Sinoexpo, is...More>>
Co-located events P-MEC/ICSE/BioPh/InnoPack/LABWorld are helping to build improved partnerships and drive GMP standards across the region CPhI announces that CPhI China, an event organised by UBM Live and UBM Sinoexpo, is...More>>
Nuvo Research to Complete Share Consolidation
Nuvo Research to Complete Share Consolidation
MISSISSAUGA, ON, May 7, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the...More>>
MISSISSAUGA, ON, May 7, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the...More>>
Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two new pooled analyses of phase III data with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, presented...More>>
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two new pooled analyses of phase III data with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, presented...More>>
Hologic Announces Second Quarter Fiscal 2013 Operating Results
Hologic Announces Second Quarter Fiscal 2013 Operating Results
Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare...More>>
Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare...More>>
Catamaran to Present at Bank of America Merrill Lynch 2013 Health Care Conference
Catamaran to Present at Bank of America Merrill Lynch 2013 Health Care Conference
LISLE, IL, May 6, 2013 /PRNewswire/ - Catamaran (NASDAQ: CTRX) (TSX: CCT), a leading provider of technology and pharmacy benefit management (PBM) services, announces that Jeff Park, Executive Vice President and Chief...More>>
LISLE, IL, May 6, 2013 /PRNewswire/ - Catamaran (NASDAQ: CTRX) (TSX: CCT), a leading provider of technology and pharmacy benefit management (PBM) services, announces that Jeff Park, Executive Vice President and Chief...More>>
New Breakthrough Treatment For Evaporative Dry Eye Disease Introduced By Dry Eye Specialist, Mark R. Mandel, M.D.
New Breakthrough Treatment For Evaporative Dry Eye Disease Introduced By Dry Eye Specialist, Mark R. Mandel, M.D.
Mark R. Mandel, M.D. , subspecialist in external eye conditions and dry eye, in practice in the Bay Area for 30 years, today announced that he is the first in the Northern California area to introduce a new treatment for the...More>>
Mark R. Mandel, M.D. , subspecialist in external eye conditions and dry eye, in practice in the Bay Area for 30 years, today announced that he is the first in the Northern California area to introduce a new treatment for the...More>>
The Elsevier Foundation Calls for 2013 New Scholars and Innovative Libraries Projects
The Elsevier Foundation Calls for 2013 New Scholars and Innovative Libraries Projects
June 24th deadline for 1-page applications to promote gender equality in academia and build capacity in developing world libraries The Elsevier Foundation is seeking new grant proposals for the 2013 New Scholars and...More>>
June 24th deadline for 1-page applications to promote gender equality in academia and build capacity in developing world libraries The Elsevier Foundation is seeking new grant proposals for the 2013 New Scholars and...More>>
MedImmune To Present Seven Posters On Influenza, Respiratory Syncytial Virus At The Annual Pediatric Academic Societies Meeting
MedImmune To Present Seven Posters On Influenza, Respiratory Syncytial Virus At The Annual Pediatric Academic Societies Meeting
MedImmune announced today it will conduct seven poster and/or presentations at the Pediatric Academic Societies (PAS) Meeting at the Walter E. Washington Convention Center in Washington DC, May 4-7, 2013. These abstracts...More>>
MedImmune announced today it will conduct seven poster and/or presentations at the Pediatric Academic Societies (PAS) Meeting at the Walter E. Washington Convention Center in Washington DC, May 4-7, 2013. These abstracts...More>>
Abstract on PreDx® Finger Stick Performance Chosen for Oral Presentations at AACE Annual Scientific & Clinical Congress
Abstract on PreDx® Finger Stick Performance Chosen for Oral Presentations at AACE Annual Scientific & Clinical Congress
Tethys Bioscience has announced the selection of their abstract "PreDx Finger Stick: Diabetes risk stratification of prediabetic patients from conveniently collected capillary blood," for Oral Presentation on May 4, 2013, at...More>>
Tethys Bioscience has announced the selection of their abstract "PreDx Finger Stick: Diabetes risk stratification of prediabetic patients from conveniently collected capillary blood," for Oral Presentation on May 4, 2013, at...More>>
Transportation Insight Introduces Extended LEAN™ to the Shingo Prize Community
Transportation Insight Introduces Extended LEAN™ to the Shingo Prize Community
Global third-party logistics provider Transportation Insight will be introducing its transformational Extended LEAN methodology to the Shingo Prize community at the 25th Annual Shingo Prize International Conference in Provo,...More>>
Global third-party logistics provider Transportation Insight will be introducing its transformational Extended LEAN methodology to the Shingo Prize community at the 25th Annual Shingo Prize International Conference in Provo,...More>>
Top New York Pediatric Gastroenterologist Joins The Colief® Colic Council
Top New York Pediatric Gastroenterologist Joins The Colief® Colic Council
Joel Lavine, M.D., Ph.D., professor of pediatrics and chief of pediatric gastroenterology, hepatology and nutrition at Columbia University Medical Center, is the newest member of the Colief® Colic Council, a group of experts...More>>
Joel Lavine, M.D., Ph.D., professor of pediatrics and chief of pediatric gastroenterology, hepatology and nutrition at Columbia University Medical Center, is the newest member of the Colief® Colic Council, a group of experts...More>>
Low-Dose Oral Contraceptives May Increase Risk of Pelvic Pain During Sexual Climax
Low-Dose Oral Contraceptives May Increase Risk of Pelvic Pain During Sexual Climax
Low-dose (low estrogen) oral contraceptives (OCPs) may increase a woman's risk for chronic pelvic pain symptoms (CPPS) and even pain during sexual climax, according to a new study. This study will be presented to...More>>
Low-dose (low estrogen) oral contraceptives (OCPs) may increase a woman's risk for chronic pelvic pain symptoms (CPPS) and even pain during sexual climax, according to a new study. This study will be presented to...More>>
STD Med, Inc. Receives Second Brazil GP Approval And Adds Med-Tech Regulatory Consulting Service
STD Med, Inc. Receives Second Brazil GP Approval And Adds Med-Tech Regulatory Consulting Service
STD Med, Inc. is pleased to announce that it has received a second Certificate of Good Practices for Manufacturing of Class III Medical Devices from ANVISA, the Brazilian National Surveillance Agency (Agencia Nacional de...More>>
STD Med, Inc. is pleased to announce that it has received a second Certificate of Good Practices for Manufacturing of Class III Medical Devices from ANVISA, the Brazilian National Surveillance Agency (Agencia Nacional de...More>>
Misonix, Inc. To Report Financial Results For The Third Quarter Fiscal 2013 On Thursday, May 9, 2013
Misonix, Inc. To Report Financial Results For The Third Quarter Fiscal 2013 On Thursday, May 9, 2013
Misonix, Inc. (Nasdaq: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery,...More>>
Misonix, Inc. (Nasdaq: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery,...More>>
Cell Therapeutics Reports First Quarter 2013 Financial Results
Cell Therapeutics Reports First Quarter 2013 Financial Results
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2013.More>>
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2013.More>>
Pivotal's Founder and Chairman Dr. George Jackowski receives Queen Elizabeth II Diamond Jubilee Medal
Pivotal's Founder and Chairman Dr. George Jackowski receives Queen Elizabeth II Diamond Jubilee Medal
WOODBRIDGE, ON, May 2, 2013 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is...More>>
WOODBRIDGE, ON, May 2, 2013 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is...More>>
CellAegis Devices Announces Second Clinical Program to Use the Company's Noninvasive autoRIC™ Device for Chronic Remote Ischemic Conditioning (CRIC) following Acute Myocardial Infarction (AMI)
CellAegis Devices Announces Second Clinical Program to Use the Company's Noninvasive autoRIC™ Device for Chronic Remote Ischemic Conditioning (CRIC) following Acute Myocardial Infarction (AMI)
CellAegis Devices, Inc., announced today the first clinical trial program in the European Union to evaluate the use of the Company's autoRIC™ Device for Chronic Remote Ischemic Conditioning (CRIC). In the DREAM study...More>>
CellAegis Devices, Inc., announced today the first clinical trial program in the European Union to evaluate the use of the Company's autoRIC™ Device for Chronic Remote Ischemic Conditioning (CRIC). In the DREAM study...More>>
Catamaran Corporation Announces Strong First Quarter Financial Results
Catamaran Corporation Announces Strong First Quarter Financial Results
-Revenue of $3.2 billion increases 88% versus Q1 2012-More>>
-Revenue of $3.2 billion increases 88% versus Q1 2012-More>>
ThromboGenics' JETREA® Available in Germany Public and Private Market
ThromboGenics' JETREA® Available in Germany Public and Private Market
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® in...More>>
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® in...More>>
Nuvo Research announces 2013 First Quarter Results
Nuvo Research announces 2013 First Quarter Results
MISSISSAUGA, ON, May 1, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune...More>>
MISSISSAUGA, ON, May 1, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune...More>>

Paula's Health NotesLas Vegas Health NewsMore>>
Woman at Risk for Cancer Opts for Mastectomy
Woman at Risk for Cancer Opts for Mastectomy
Updated: Wednesday, May 15 2013 4:58 PM EDT2013-05-15 20:58:55 GMT

Actress Angelina Jolie's decision to have a double mastectomy is sparking strong emotions from women over the questions of whether genetic testing for breast cancer is for everyone,.More>>
Actress Angelina Jolie's decision to have a double mastectomy is sparking strong emotions from women over the questions of whether genetic testing for breast cancer is for everyone, and whether women should have breast surgery, even if they don't have cancer.More>>
Neighborhoods: Downtown
SLIDESHOW: Race for the Cure
SLIDESHOW: Race for the Cure
8 News Now
If you were one of the nearly 15,000 people who came downtown Saturday morning for Race for the Cure, see if you made it into our slideshow.More>>
Las Vegas Man's Battle with Breast Cancer
Las Vegas Man's Battle with Breast Cancer
Updated: Thursday, May 2 2013 6:25 PM EDT2013-05-02 22:25:44 GMT
We usually think of women when we talk about breast cancer, but men are affected as wellin fact about 2-thousand men in this country country are diagnosed with breast cancer everyone, and about 400 die from the disease.More>>
Most discussions about breast cancer tend to focus on women, but men are also affected by the disease. Every year, nearly 2,000 men in this country are diagnosed with breast cancer.More>>
Nevada 2nd Highest in Country for Middle Age Suicide
Nevada 2nd Highest in Country for Middle Age Suicide
Updated: Thursday, May 2 2013 3:21 PM EDT2013-05-02 19:21:04 GMT
LAS VEGAS (AP) -- New government data show Nevada has the second-highest suicide rate in the country among people aged 35 to 64, although the rise in the rate was much slower than it was nationally. TheMore>>
New government data show Nevada has the second-highest suicide rate in the country among people aged 35 to 64, although the rise in the rate was much slower than it was nationally.More>>
Race For The Cure: Woman Survives Rare Breast Cancer
Race For The Cure: Woman Survives Rare Breast Cancer
A young single mother learned she had a rare form of breast cancer. After a double mastectomy, she struggled to move on, but the love she had for her son motivated her to survive. She is raising money for her medical expenses.More>>
Doctors Discuss Stroke Warning Signs
Doctors Discuss Stroke Warning Signs
Wednesday kicks off American Stroke Month, and medical professionals want people to recognize the warning signs of strokes. Two doctors and stroke experts discussed the dangers on 8 News NOW This Morning.More>>

News Releases via PR NewswireNews Releases via PR NewswireMore>>
Entertainment News Releases via PRNewswire
Entertainment
Entertainment News Releases via PRNewswire
Travel
Travel News Releases via PRNewswire
Political Campaigns
Political Campaigns News Releases via PRNewswire
Medicine & Pharmaceuticals
Medicine & Pharmaceuticals News Releases via PRNewswire
Film & Motion Picture News Releases via PRNewswire
Film & Motion Picture
Film & Motion Picture News Releases via PRNewswire
Economic News and Analysis
Economic News Releases via PRNewswire
Computer Software
Computer Software News Releases via PRNewswire
Computer Networks
Computer Networks News Releases via PRNewswire
Computer Hardware
Computer Hardware News Releases via PRNewswire
Biotech News Releases via PRNewswire
Biotechnology
Biotechnology News Releases via PRNewswire

Medicine & Pharmaceuticals - 8 News NOW

Medicine & Pharmaceuticals News Releases via PRNewswireMore>>